Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2023 Dec;30(1):2164094.
doi: 10.1080/10717544.2022.2164094.

Fabrication, assessment, and optimization of alendronate sodium nanoemulsion-based injectable in-situ gel formulation for management of osteoporosis

Wesam H Abdulaal  1   2 , Khaled M Hosny  3 , Nabil A Alhakamy  3   4 , Rana B Bakhaidar  3 , Yasir Almuhanna  5 , Fahad Y Sabei  6 , Mohammed Alissa  7 , Mohammed Majrashi  8 , Jawaher Abdullah Alamoudi  9 , Mohannad S Hazzazi  10   11 , Ayman Jafer  10 , Rasha A Khallaf  12
Affiliations

Fabrication, assessment, and optimization of alendronate sodium nanoemulsion-based injectable in-situ gel formulation for management of osteoporosis

Wesam H Abdulaal et al. Drug Deliv. 2023 Dec.

Abstract

Low bone mass, degeneration of bone tissue, and disruption of bone microarchitecture are all symptoms of the disease osteoporosis, which can decrease bone strength and increase the risk of fractures. The main objective of the current study was to use a phospholipid-based phase separation in-situ gel (PPSG) in combination with an alendronate sodium nanoemulsion (ALS-NE) to help prevent bone resorption in rats. The effect of factors such as concentrations of the ALS aqueous solution, surfactant Plurol Oleique CC 497, and Maisine CC oil on nanoemulsion characteristics such as stability index and globular size was investigated using an l-optimal coordinate exchange statistical design. Injectable PPSG with the best nanoemulsion formulation was tested for viscosity, gel strength, water absorption, and in-vitro ALS release. ALS retention in the rats' muscles was measured after 30 days. The droplet size and stability index of the optimal nanoemulsion were 90 ± 2.0 nm and 85 ± 1.9%, respectively. When mixed with water, the optimal ALS-NE-loaded PPSG became viscous and achieved 36 seconds of gel strength, which was adequate for an injectable in-situ formulation. In comparison with the ALS solution-loaded in-situ gel, the newly created optimal ALS-NE-loaded PPSG produced the sustained and regulated release of ALS; hence, a higher percentage of ALS remained in rats' muscles after 30 days. PPSG that has been loaded with an ALS-NE may therefore be a more auspicious, productive, and effective platform for osteoporosis treatment than conventional oral forms.

Keywords: In situ gel; PPSG; alendronate sodium; design of experiment; nanoemulsion; osteoporosis.

PubMed Disclaimer

Conflict of interest statement

No potential conflict of interest was reported by the author(s).

Figures

Figure 1.
Figure 1.
Perturbation graph (a), contour plot (b), and 3 D surface plot (c) illustrating the influence of different factors on the droplet size (Y1) of various ALS-NE formulations.
Figure 2.
Figure 2.
Perturbation graph (a), contour plot (b), and 3 D surface plot (c) illustrating the influence of different factors on the stability index (Y1) of various ALS-NE formulations.
Figure 3.
Figure 3.
Desirability ramp and bar chart for optimization process. (a) The desirability ramp illustrated the levels of studied factors and anticipated estimations for dependent variables of the optimized formulation. (b) The bar chart presents the desirability assessments for the collective responses.
Figure 4.
Figure 4.
In-vitro release profiles of ALS aqueous solution from optimized ALS-NE–loaded PPSG and control ALS solution containing PPSG (mean ± SD, n = 3).
Figure 5.
Figure 5.
The percentage of ALS released in the muscles for various tested groups after 30 days.
See this image and copyright information in PMC

References

    1. Abdelbary A, Salem HF, Khallaf RA, et al. (2017). Mucoadhesive niosomal in situ gel for ocular tissue targeting: in vitro and in vivo evaluation of lomefloxacin hydrochloride. Pharm Dev Technol 22:1–9. - PubMed
    1. Alhakamy NA, Hosny KM, Aldryhim AY, et al. (2022). Development and optimization of ofloxacin as solid lipid nanoparticles for enhancement of its ocular activity. J Drug Deliv Sci Technol 72:103373.
    1. Ali SA, Sindi AM, Mair YH, et al. (2021). Oral gel loaded by ethotransfersomes of antifungal drug for oral thrush: preparation, characterization, and assessment of antifungal activity. J Drug Deliv Sci Technol 66:102841.
    1. Alkhalidi HM, Naguib GH, Kurakula M, et al. (2018). In vitro and preclinical assessment of factorial design based nanoethosomal transdermal film formulation of mefenamic acid to overcome barriers to its use in relieving pain and inflammation. J Drug Deliv Sci Technol 48:450–6.
    1. Bauer DC, Black D, Ensrud K, et al. (2000). Upper gastrointestinal tract safety profile of alendronate: the fracture intervention trial. Arch Intern Med 160:517–25. - PubMed